國立虎尾科技大學 |

Formulating Poorly Water Soluble Drugs

Record Type:	Language materials, printed : Monograph/item
Title/Author:	Formulating Poorly Water Soluble Drugs/ edited by Robert O. Williams III, Daniel A. Davis Jr., Dave A. Miller.
other author:	Miller, Dave A.
Description:	XII, 693 p. 280 illus., 138 illus. in color.online resource. :
Contained By:	Springer Nature eBook
Subject:	Medical Biochemistry. -
Online resource:	https://doi.org/10.1007/978-3-030-88719-3
ISBN:	9783030887193

Formulating Poorly Water Soluble Drugs
Formulating Poorly Water Soluble Drugs[electronic resource] /edited by Robert O. Williams III, Daniel A. Davis Jr., Dave A. Miller. - 3rd ed. 2022. - XII, 693 p. 280 illus., 138 illus. in color.online resource. - AAPS Advances in the Pharmaceutical Sciences Series,502210-738X ;. - AAPS Advances in the Pharmaceutical Sciences Series,20.

Route-Specific Challenges in the Delivery of Poorly Water-Soluble Drugs -- Optimizing the Formulation of Poorly Water-Soluble Drugs -- Solid-State Techniques for Improving Solubility -- Mechanical Particle-Size Reduction Techniques -- Co-solvent and Complexation Systems -- Injectable Formulations of Poorly Water-Soluble Drugs -- Lipid-Based Formulations -- Structured Development Approach for Amorphous Systems -- Melt Extrusion -- Spray-Drying Technology -- Pharmaceutical Cryogenic Technologies -- Precipitation Technologies for Nanoparticle Production -- Emerging Technologies to Increase the Bioavailability of Poorly Water-Soluble Drugs -- Scientific and Regulatory Considerations for Development and Commercialization of Poorly Water-Soluble Drugs.

The objective of this third edition is to consolidate within a single text the most current knowledge, practical methods, and regulatory considerations pertaining to formulations development with poorly water-soluble molecules. A pharmaceutical scientist’s approach toward solubility enhancement of a poorly water-soluble molecule typically includes detailed characterization of the compound’s physiochemical properties, solid-state modifications, advanced formulation design, non-conventional process technologies, advanced analytical characterization, and specialized product performance analysis techniques. The scientist must also be aware of the unique regulatory considerations pertaining to the non-conventional approaches often utilized for poorly water-soluble drugs. One faced with the challenge of developing a drug product from a poorly soluble compound must possess at a minimum a working knowledge of each of the above mentioned facets and detailed knowledge of most. In light of the magnitude of the growing solubility problem to drug development, this is a significant burden especially when considering that knowledge in most of these areas is relatively new and continues to develop. Highlights the most recent advancements reported in the literature on technologies to improve the dissolution and bioavailability of poorly water soluble drugs Provides a comprehensive discussion of new technologies developed and recently over 40% updated new content Essential read for scientists and researchers in pharmaceutical, chemical, and agricultural industries since over 80% of newly discovered drugs are poorly water soluble.

ISBN: 9783030887193

Standard No.: 10.1007/978-3-030-88719-3doiSubjects--Topical Terms:

668897
Medical Biochemistry.

LC Class. No.: RS400-431

Dewey Class. No.: 615.19

Formulating Poorly Water Soluble Drugs
LDR:03889nam a22004095i 4500 001 1090065
003 DE-He213
005 20220519132730.0
007 cr nn 008mamaa
008 221228s2022 sz | s |||| 0|eng d
020 $a 9783030887193 $9 978-3-030-88719-3
024 7 $a 10.1007/978-3-030-88719-3 $2 doi
035 $a 978-3-030-88719-3
050 4 $a RS400-431
072 7 $a PSB $2 bicssc
072 7 $a MED072000 $2 bisacsh
072 7 $a PNB $2 thema
082 0 4 $a 615.19 $2 23
245 1 0 $a Formulating Poorly Water Soluble Drugs $h [electronic resource] / $c edited by Robert O. Williams III, Daniel A. Davis Jr., Dave A. Miller.
250 $a 3rd ed. 2022.
264 1 $a Cham : $b Springer International Publishing : $b Imprint: Springer, $c 2022.
300 $a XII, 693 p. 280 illus., 138 illus. in color. $b online resource.
336 $a text $b txt $2 rdacontent
337 $a computer $b c $2 rdamedia
338 $a online resource $b cr $2 rdacarrier
347 $a text file $b PDF $2 rda
490 1 $a AAPS Advances in the Pharmaceutical Sciences Series, $x 2210-738X ; $v 50
505 0 $a Route-Specific Challenges in the Delivery of Poorly Water-Soluble Drugs -- Optimizing the Formulation of Poorly Water-Soluble Drugs -- Solid-State Techniques for Improving Solubility -- Mechanical Particle-Size Reduction Techniques -- Co-solvent and Complexation Systems -- Injectable Formulations of Poorly Water-Soluble Drugs -- Lipid-Based Formulations -- Structured Development Approach for Amorphous Systems -- Melt Extrusion -- Spray-Drying Technology -- Pharmaceutical Cryogenic Technologies -- Precipitation Technologies for Nanoparticle Production -- Emerging Technologies to Increase the Bioavailability of Poorly Water-Soluble Drugs -- Scientific and Regulatory Considerations for Development and Commercialization of Poorly Water-Soluble Drugs.
520 $a The objective of this third edition is to consolidate within a single text the most current knowledge, practical methods, and regulatory considerations pertaining to formulations development with poorly water-soluble molecules. A pharmaceutical scientist’s approach toward solubility enhancement of a poorly water-soluble molecule typically includes detailed characterization of the compound’s physiochemical properties, solid-state modifications, advanced formulation design, non-conventional process technologies, advanced analytical characterization, and specialized product performance analysis techniques. The scientist must also be aware of the unique regulatory considerations pertaining to the non-conventional approaches often utilized for poorly water-soluble drugs. One faced with the challenge of developing a drug product from a poorly soluble compound must possess at a minimum a working knowledge of each of the above mentioned facets and detailed knowledge of most. In light of the magnitude of the growing solubility problem to drug development, this is a significant burden especially when considering that knowledge in most of these areas is relatively new and continues to develop. Highlights the most recent advancements reported in the literature on technologies to improve the dissolution and bioavailability of poorly water soluble drugs Provides a comprehensive discussion of new technologies developed and recently over 40% updated new content Essential read for scientists and researchers in pharmaceutical, chemical, and agricultural industries since over 80% of newly discovered drugs are poorly water soluble.
650 2 4 $a Medical Biochemistry. $3 668897
650 1 4 $a Pharmaceutics. $3 1366841
650 0 $a Clinical biochemistry. $3 591508
650 0 $a Pharmacology. $3 583819
650 0 $a Pharmaceutical chemistry. $3 581965
700 1 $a Miller, Dave A. $4 edt $4 http://id.loc.gov/vocabulary/relators/edt $3 889161
700 1 $a Davis Jr., Daniel A. $e editor. $4 edt $4 http://id.loc.gov/vocabulary/relators/edt $3 1397405
700 1 $a Williams III, Robert O. $e editor. $4 edt $4 http://id.loc.gov/vocabulary/relators/edt $3 1273037
710 2 $a SpringerLink (Online service) $3 593884
773 0 $t Springer Nature eBook
776 0 8 $i Printed edition: $z 9783030887186
776 0 8 $i Printed edition: $z 9783030887209
776 0 8 $i Printed edition: $z 9783030887216
830 0 $a AAPS Advances in the Pharmaceutical Sciences Series, $x 2210-7371 ; $v 20 $3 1255084
856 4 0 $u https://doi.org/10.1007/978-3-030-88719-3
912 $a ZDB-2-SBL
912 $a ZDB-2-SXB
950 $a Biomedical and Life Sciences (SpringerNature-11642)
950 $a Biomedical and Life Sciences (R0) (SpringerNature-43708)